Drugmaker Eli Lilly announces new plant in Pennsylvania as part of domestic expansion
Drugmaker Eli Lilly and Co. says it will build a $3.5 billion manufacturing plant in Pennsylvania, as the company expands domestic production and capitalizes on rising sales of treatments for obesity and diabetes.
HARRISBURG, Pa. — Drugmaker Eli Lilly and Co. said Friday it will build a $3.5 billion manufacturing plant in Pennsylvania, as the company expands domestic production and capitalizes on rising sales of treatments for obesity and diabetes.
Indianapolis-based Eli Lilly, maker of the weight-loss treatment Zepbound and the diabetes drug Mounjaro, is in the midst of a broader national expansion that includes new plants announced in Texas, Virginia and Alabama. Another facility is under construction in Indiana.
The company said the new plant in Fogelsville, just outside Allentown, will make injectable drugs and devices, including producing the weight-loss drug retatrutide, a once-weekly injectable drug that is still under study and not available for public use.
Construction should begin this year and end in 2031, it is said.
Sales of Zepbound and Mounjaro brought the company’s third-quarter profit to a record $5.58 billion. Third-quarter revenue was $17.6 billion, up more than 50% from the same quarter a year earlier. Zepbound and Mounjaro alone accounted for $10 billion in revenue in the company’s third quarter.
